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Introduction
BREAST cancer is the most common cancer 
among women, with an estimated 1.7 million 
new cases occurring in 2012 (1). More than 
half of cases and more than 60 percent of 
deaths now occur in low- and middle-income 
countries (LMICs) and these proportions 
are expected to increase. While the absolute 
number of deaths in industrialized countries 
will increase 23 percent by 2030, those in less 
developed countries will increase 55 percent 
(1). These grim figures demand renewed efforts 
to diagnose early stage breast cancer in LMICs 
when it is potentially curable.
The importance of early detection and 
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Abstract
Purpose: Breast cancer is the most common cancer among women worldwide, with an estimated 
1.7 million new cases occurring in 2012. The majority of cases and deaths occur in low- and middle-
income countries (LMICs), where population-based mammography screening is not available and 
countries must rely on clinical breast examination (CBE). Since ultrasound has the potential to reduce 
unnecessary biopsies by triaging women with palpable or focal breast findings at CBE, we searched 
for evidence in the literature on the effectiveness of ultrasound in detecting potential breast cancer 
following positive CBE findings.
Methods: We reviewed the literature from 2000 to 2014 for evidence on the performance of breast 
ultrasound, in the absence of mammography, used to evaluate women after a positive CBE. From 
the studies meeting our inclusion/exclusion criteria for our analysis, we extracted data on the study 
design, location, ultrasound transducer parameters, patient age, method for determining positive and 
negative cases, and number of malignancies detected/total number of women studied.
Results: We found 15 studies matching our inclusion/exclusion criteria, 9 from high-income countries 
and 6 from LMICs. Despite considerable variability in study design and patient populations, breast 
ultrasound consistently showed high sensitivity (median = 94 percent) and specificity (median = 80 
percent) for detecting breast cancer and identifying normal and benign findings not requiring a biopsy. 
Clear patterns related to transducer frequency or income level were not discernible given the variations 
in patient populations and final diagnostic determinations.
Conclusion: Our systematic review suggests that breast ultrasound following a positive CBE may be 
a powerful diagnostic test to determine those who do or do not need biopsy. We encourage further 
research in breast ultrasound use after a positive CBE in LMICs to assess the accuracy of ultrasound in 
these settings and the feasibility of widespread implementation.
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treatment of breast cancer is well recognized (2,3) and is supported 
by the observed decrease in breast cancer deaths among women 
in high-resource regions undergoing screening mammography. 
However, there is disagreement on the relative contributions of 
population screening and adjuvant therapy to the decline in deaths 
(4,5). A study that developed seven independent statistical models 
to distinguish the effects of these two factors in the United States 
reported that the contribution of screening in these models ranged 
from 28 to 65 percent (6), indicating the difficulty of evaluating the 
differential impact of interventions. All major North American 
and European groups that make recommendations on breast 
cancer screening support routine mammography, starting at age 
40 or 50 and performed every one or two years (7,8). Although 
the age of initiation and frequency of mammography exams for 
population screening has been the subject of much controversy 
(5,9,10), it remains the standard imaging technique for screening 
in developed countries. 
The debate taking place on screening mammography in 
industrialized countries is a luxury that most LMICs have not had. 
Population-based breast cancer screening using mammography 
has not been widely implemented in these regions because the 
infrastructure necessary to support screening programs, such 
as trained personnel, facilities, and equipment, is expensive 
to establish and maintain (11). In addition, the resources for 
providing effective educational and communication campaigns to 
encourage participation in screening have not been available. 
An alternative to screening mammography for low-resource 
settings is clinical breast examination (CBE), a hands-on physical 
examination and visual assessment of the breasts by a healthcare 
professional, along with a careful medical history (12,13). There 
have been no published randomized clinical trials for CBE as a 
sole screening or early detection modality (14,15). Preliminary 
results have been reported from a randomized clinical trial 
in India evaluating whether CBE can reduce the incidence of 
advanced disease and mortality from breast cancer (16). However, 
conclusive results will only become available after completion of 
three rounds of screening and further follow-up. 
The American Cancer Society recommends that women in 
their 20s and 30s have a CBE as part of a regular health exam by 
a health professional every three years and that, starting at age 
40, women should have a CBE by a health professional every year 
(17). CBE has also been suggested both for population screening in 
LMICs (9,12,18) and for evaluating women presenting with breast 
symptoms such as lumps, pain, thickening, or nipple discharge 
(19). The International Agency for Research on Cancer states in its 
2002 Handbook: “Clinical breast examination may be of particular 
importance in countries where there are insufficient resources 
for [screening] mammography and where disease is usually at an 
advanced stage at the time of diagnosis” (7).  The World Health 
Organization notes that low-income areas have the option to 
implement early diagnosis programs based on awareness of early 
symptoms and referral for confirmed diagnosis and treatment (3). 
Using CBE for screening raises the question of what the next 
steps should be after palpable masses or focal symptoms are 
identified. In well-resourced settings, a positive CBE is evaluated 
with breast imaging—mammography and/or ultrasound 
depending on the patient’s age—and biopsy is recommended 
for lesions suspicious for malignancy. Ultrasound is better able 
to differentiate solid from cystic masses than mammography 
(20-22), and it is generally acknowledged that ultrasound is an 
important tool in evaluating symptomatic women, especially 
women under age 40, whose breasts are typically denser than those 
of older women. Ultrasound is also widely used for triaging solid 
palpable masses that require a biopsy versus those that can safely 
be managed by imaging or clinical follow-up, thus reducing the 
number of unnecessary biopsies (23). For palpable breast masses, 
the American College of Radiology recommends ultrasound as 
the first imaging evaluation in women under age 30, ultrasound 
or mammography in women ages 30 to 39, and mammography 
followed by ultrasound (for most cases) in women ages 40 and older 
(24). Masses with distinct benign features on ultrasound (such as 
a simple cyst or lymph node) do not need further intervention, 
while masses with probable benign features on ultrasound can 
be followed clinically and with imaging. Masses with features 
suspicious for malignancy should undergo tissue sampling, with 
core needle biopsy (CNB) or fine needle aspiration (FNA) when 
available. The United Kingdom Association of Breast Surgery 
recommendations (25) are similar to those of the American 
College of Radiology. 
Imaging with ultrasound of clinically suspicious palpable 
findings at CBE might be useful in LMICs, where mammography 
machines are not available and many hospitals may have ultrasound 
equipment appropriate for breast imaging. Ultrasound used in this 
way could alleviate the burden of evaluating symptomatic women, 
because CBE alone has poor diagnostic accuracy for separating 
benign from malignant lumps and thus requires more tissue 
sampling than is likely needed.
In view of the potential role that ultrasound could play in 
LMICs for triaging women with palpable or focal breast findings 
at CBE, either to biopsy or to follow up clinically or with imaging, 
we searched for evidence in the literature on the effectiveness of 
ultrasound in detecting potential breast cancer following positive 
CBE findings. 
Materials and methods
We used PubMed, Google Scholar, and the Cochrane database 
to perform a systematic review of the literature regarding the 
performance of breast ultrasound in LMICs following a CBE-
positive test. Our search criteria included English-language 
literature published within the period of 2000 through 2014, using 
the following terms: palpable AND (ultrasound OR sonography 
OR ultrasonography) AND (developing countries OR low-income 
countries). We excluded the following studies: population-based 
ultrasound screening of asymptomatic women; ultrasound 
examinations performed after mammography; ultrasound 
performance measures of palpable and non-palpable lesions if 
only reported combined; and ultrasound performance limited to 
“probably benign sonographic features.”
After the primary searches, we searched the bibliographies 
of relevant papers and contacted experts in the field for further 
recommendations appropriate for our inclusion/exclusion criteria 
described above. Papers published prior to 2000 were included 
from the latter searches if they met the other inclusion criteria; two 
papers were added on this basis. While our interest was primarily 
the use of ultrasound in LMICs, we included selected studies from 
high-income countries if they met our other inclusion/exclusion 
criteria because of the scarcity of studies in LMICs, and for 
comparison purposes. From those studies meeting our inclusion/
exclusion criteria for our analysis we extracted data on the study 
design, study location, ultrasound transducer parameters, patient 
population (age), the method for determining positive and negative 
cases (fine needle aspiration, core needle biopsy and surgical 
biopsy), and the number of malignancies detected/total number 
of women studied. We also extracted ultrasound performance 
measures, including sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV). 
Results
This review covers a targeted group of studies that specifically 
report the performance of breast ultrasound, in the absence of 
or independent of mammography findings, following a positive 
CBE. Initial searches resulted in several hundred papers, which 
were assessed for relevance to our question. Our review of 
these reduced to 15 the number of papers that reported at least 
sensitivity of breast ultrasound for detection of malignancy after 
palpable masses or focal symptoms were found at CBE. 
Two studies were from low-income countries and four were 
from lower middle–income countries: these are presented in 
Table 1. The remaining nine papers reported studies in upper-
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middle or high-income countries and are presented in Table 2. We 
included two studies that evaluated performance on pre-selected 
sonographically solid lesions because of our interest in the ability 
of ultrasound to differentiate malignant from nonmalignant 
palpable lumps. Four of the six LMIC studies, and four of the nine 
upper-income studies, were prospective, while the remainder were 
retrospective. All were performed at single institutions.
Patient populations
The 15 selected studies assessed breast ultrasound performance 
in different patient populations with different breast cancer 
prevalence. Three studies restricted participants to narrow age 
ranges (under 30 years (26); under 35 years (27); 30-39 years (28)). 
Some chose to investigate all women who had palpable findings 
and imaging during a given time period (26,28), one study 
reviewed a sample of women with symptoms and imaging who 
had confirmed cancer and an age-matched sample confirmed as 
nonmalignant (29). Studies from Taiwan (30) and India (31) pre-
selected only cases identified as solid lesions on ultrasound, to see 
if ultrasound could further differentiate benign and malignant 
solid lumps. These are more restricted populations than the one 
our review initially set out to analyze, which included all palpable 
lesions, whether solid or cystic.
Equipment used for ultrasound
Most transducers used in studies from lower-income countries 
(Table 1) had a frequency of 7.5 MHz, with one study using a 12 MHz 
probe for some cases. In the higher-income studies, frequencies of 
the probes ranged from 6 to 14 MHz but were usually higher than 
in the lower-income country studies. One study in lower-income 
countries and two studies in the higher-income group did not 
report on the transducer frequency used (32-34). 
Definition of ultrasound detection of malignancy 
Ultrasound detection of malignancy in the selected studies 
was based on either the American College of Radiology Breast 
Imaging Reporting and Database System (BI-RADS) Atlas (4th 
edition) (35), which characterizes lesions using a specific lexicon 
and assigns them to a category based on a level of suspicion for 
malignancy; or on descriptors similar to those of BI-RADS, such as 
shape, margins, echogenicity, and ratios of dimensions. 
In most studies, the gold standard for assessing ultrasound 
performance was histopathology based on either CNB or surgical 
excision; however, two studies of women under the age of 40 in the 
United States used 24 months of clinical and tumor registry follow-
up for the majority of those with benign findings at ultrasound, 
and histopathology for those suspected of having a malignancy 
(26,28). One study used only FNA and cytology as the reference 
standard (31), while the rest used some combination of FNA, CNB, 
or surgical biopsy. Intervention methods for tissue sampling are 
given for each study in the tables below. Sensitivity, specificity, and 
other performance measures were reported for detecting cancer; 
some papers also reported performance for differentiating cysts 
from solid masses, but we report only performance in detecting 
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Table I. Performance of breast ultrasound in symptomatic women in low and lower-middle–income countriesa
Study/design Location
(Economic Levela)
Transducer 
Frequency
Mean Age
(range)
Method for 
Diagnosisb
Number 
malignant/
Total Cases
Ultrasound 
Performancec
(in %)
Ngotho 2013(27)
Prospective
Kenya
(Low Income)
7.5-12 MHz 25.5
(18–34)
FNA, CNB 6/58 Sensitivity: 100
Specificity: 94.2
NPV: 100
PPV: 66.7
Gonzaga 2010(36)
Prospective
Uganda
(Low Income)
7.0 MHz N/A
(40%: 30–39 
20%: 20–29)
CNB, SBx 7/80 Sensitivity: 57.1
Irurhe 2012(37)
Prospective
Nigeria
(Lower-middle 
Income)
7.5 MHz 42
(18–59)
FNA, CNB 13/100 Sensitivity: 100
Specificity: 96.6
NPV: 100
PPV: 81.3
Devolli-Disha 2009(39)
Prospective
Kosovo
(Lower-middle 
Income)
7.5 MHz 56
(30–77)
SBx 259/546 Sensitivity: 72.6
Specificity 88.5
Singh 2008(33)
Retrospective
India
(Lower-middle 
Income)
Not Stated 41
N/A
FNA, CNB, SBx 20/100 Sensitivity: 65.0
Pande 2003(31)
Prospective
India
(Lower-middle 
Income)
7.5 MHz 41
(17-80)
FNA 19/36d Sensitivity: 95.0
Specificity: 94.1
NPV: 93.8
PPV: 96.0
a Defined by the World Bank list of economies (51) 
b FNA = fine needle aspiration; CNB = core needle biopsy; SBx = Surgical biopsy 
c NPV = Negative Predictive Value; PPV = Positive Predictive Value
d Included only cases with positive findings on ultrasounds (e.g. masses and cysts)
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Table II. Performance of breast ultrasound in symptomatic women in upper-middle and high-income countriesa
Study/design Location
(Economic 
Levela)
Transducer 
Frequency
Mean Age
(range)
Method For 
Diagnosisb
Number 
malignant/
Total 
Ultrasound 
Performancec
(in %)
Li 2014(38)
Retrospective
China
(Upper-Middle 
Income)
7-14 MHz Not Stated CNB, SBx 2294/5296 Sensitivity: 97.9
Specificity: 49.7
Akbari 2012(32)
Prospective
Iran 
(Upper-Middle 
Income)
Not Stated Not Stated 
(30–79)
FNA, CNB, SBx 95/164 Sensitivity: 69.5
Specificity: 49.3
NPV: 65.3
PPV: 54.0
Zhu 2008(40)
Prospective
China
(Upper-Middle 
Income)
6-13 MHz 
46
(17– 83)
SBx 69/139 Sensitivity: 94.2
Specificity: 87.1
Lehman 2012(28) USA
(High Income)
12 MHz 35
(30–39)
CNB, SBX, 2-year 
follow-up
23/1208 Sensitivity: 95.7
Specificity: 89.2
NPV: 99.9
PPV: 13.2
Loving 2010(26)
Retrospective
USA
(High Income)
12 MHz 24
(12–29)
 
FNA, CNB, SBx, 
2-year follow-up 
3/1091 Sensitivity: 100
Specificity: 80.5
NPV: 100
PPV: 1.9
Chen 2004(30)
Prospective
Taiwan
(High Income)
7.5-10.0 MHz Not Stated 
(14–83)
CNB, SBx 391/1203 solid 
massesd
Sensitivity: 79.3
Specificity: 89.3
NPV: 90.0
PPV: 78.1
Houssami 
2003(29)
Retrospective
Australia
(High Income)
7.5-11.5 MHz Not Stated (25-55) FNA, SBx, 2-year 
follow-up 
240/473 Sensitivity: 81.7
Specificity: 88.0
Moss 1999(34)
Prospective
United Kingdom
(High Income)
Not Stated Not Stated SBx 256/456 Sensitivity: 88.9
Specificity: 77.9
Yang 1996(41) Hong Kong
(High Income)
5-10 MHz 37
(13–85)
FNA, SBx 67/408 Sensitivity: 97.0
Specificity: 96.88
NPV: 99.4
PPV: 85.3
a  Defined by the World Bank list of economies (51) 
b  F NA = fine needle aspiration; CNB = core needle biopsy; SBx = Surgical biopsy 
c NPV = Negative Predictive Value; PPV = Positive Predictive Value
d  Included only cases with positive findings on ultrasounds (e.g. masses and cysts)
malignancy. Eight studies did not specify the histological types 
of malignancies diagnosed (27,31-34,36-38) while the remaining 
seven gave histological definitions of malignancies (26,28-30,39-
41); none of the latter excluded ductal carcinoma in situ.
Performance of ultrasound 
In general, studies using more powerful transducers reported 
higher sensitivities: of eight studies using probes with frequencies 
of at least 10 MHz, sensitivities ranged from 79.3 to 100 percent, 
with a median of 96 percent. In the four studies using probes 
with frequencies of 7 or 7.5 MHz, the range was from 57.1 to 100 
percent, with a median of 84 percent. Of note, two small studies 
using probes with frequency of 7.5 MHz obtained sensitivities of 95 
and 100 percent, in lower middle–income countries.
The number of cases reported in studies from LMICs was 
smaller than those reported from higher income countries, 
ranging from 36 to 546 cases with a median of 90. Sensitivities in 
all six studies ranged from 57.1 to 100 percent, with a median value 
of 84 percent, while median specificity was 94.2 percent (Table 1). 
In the two studies that included only solid lumps, sensitivity and 
specificity were 79.3 percent and 89.3 percent, respectively, for the 
Taiwanese study and 95 percent and 94.1 percent, respectively, for 
the small study from India.
In aggregate, studies from upper-middle and high-income 
countries showed that ultrasound detected 3,201 cancers (range 
3–2,246) among the 3,438 cases included in the studies. Overall, 
the median sensitivity was 94.2 percent (range 69–100), median 
specificity was 87.1 percent (range 49–97), median PPV was 54.0 
percent (range 2–85), and median NPV was 99.4 (range 65–100). 
Four studies reviewed more than 1,000 cases each (26,28,30,38), 
reporting sensitivities of 79.3 to 100 percent, with a median value 
of 96.8 percent (Table 2).
In two large studies conducted in the United States, sensitivity 
of ultrasound for detecting malignancy in women ages 30 to 39  was 
95.7 percent and specificity was 89.2 percent (28), while for women 
younger than 30 years of age the numbers were 100 percent and 80.5 
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percent, respectively (26). In both studies, most of the women with 
benign findings at ultrasound did not have histological examination 
of the tissue, but instead were followed by imaging surveillance 
and tumor registries for at least 24 months. Because the study 
populations were not preselected for women who had biopsies, 
the number of malignant cases present was much lower than for 
studies that intentionally reviewed cases known retrospectively 
to have been malignant. Another retrospective study in a high-
income setting chose to evaluate ultrasound performance on equal 
numbers of cases with and without malignant diagnoses, reporting 
a sensitivity of 81.7 percent and specificity of 88.0 percent (29).
Discussion
No randomized clinical trials have been conducted to evaluate 
the efficacy of breast ultrasound for detection of malignancy 
in symptomatic women; however, our review identified a 
number of prospective and retrospective analyses on ultrasound 
performance for palpable findings following a CBE. Sensitivity 
varied considerably across the studies, but in 10 of the 15 studies 
sensitivity was at least 80 percent and median specificity was 88 
percent. The sensitivity, specificity, and NPV of ultrasound were 
generally high, while PPV was often low. The sensitivities observed 
in high-income countries were generally higher than in LMICs, 
and the specificities observed in LMICs were generally higher 
than in high-income countries; however, despite the wide range 
of performance in LMICs, it is clear that it is possible to achieve 
good sensitivity even with modest resources. The composition of 
the patient populations in LMICs may include more women with 
larger masses, since they are more likely to represent prevalent 
rather than incident disease, but this is difficult to distinguish 
from these studies. Sensitivity may also be overestimated in LMICs 
if screen-negative women were not followed, since this may lead to 
under-ascertainment of false negatives. Nevertheless, the reported 
performance of breast ultrasound following a positive CBE 
was generally favorable across all studies and warrants further 
evaluation. 
The most comprehensive guidelines on early detection, 
diagnosis, and treatment of breast cancer in LMICs come from 
the Breast Health Global Initiative, an international program 
cofounded in 2002 by the Fred Hutchinson Cancer Research 
Center and Susan G. Komen for the Cure (42). The Breast Health 
Global Initiative has held five global summits to address various 
aspects of breast cancer in LMICs. In a report on the 2002 summit, 
researchers noted that in cases with a finding of a palpable mass, 
ultrasound could be used to distinguish cysts from solid masses 
and provides “an estimation of the likelihood of malignancy in a 
solid mass” (43). In subsequent publications, a tiered system was 
defined to stratify national health resources into four levels—basic, 
limited, enhanced, and maximal (44,45)—with recommendations 
at each level to match the economic capacities of countries. At 
the “basic” resource level, clinical history and CBE may be the 
only detection modalities available, while at the “limited” level, 
countries are encouraged to perform outreach and education 
promoting CBE for age groups at higher risk, and to use diagnostic 
ultrasound (with mammography, if available) for women with 
positive findings at CBE. 
Many of the reports emphasized the need for high-quality 
equipment, careful operator training, and availability of trained 
radiologists for accurate interpretation. Classifying solid masses 
as malignant or benign typically requires skilled radiologists (30); 
however, training non-physician sonographers for some aspects of 
breast imaging could build human capacity in LMICs. Successful 
training of midwives in Zambia and Uganda for conducting limited 
screening ultrasound exams for obstetric use (46,47) demonstrates 
the potential for this approach. Other researchers in Uganda have 
pointed out that ultrasound equipment is tenfold more available 
in sub-Saharan Africa than are mammography machines, which 
are twice as expensive and dedicated to only one type of procedure 
(48). 
Although traditional ultrasound devices are widely available 
in LMICs (49), transducers of appropriate frequency may need to 
be sourced, or existing transducers modified for breast evaluation. 
According to the American College of Radiology, “breast 
ultrasound should be performed with a high-resolution real-time 
linear array scanner operating at a center frequency of at least 10 
MHz and preferably higher” (50). Our analysis found that many 
studies used suboptimal equipment, although that was probably 
the best available transducer. While we did note higher sensitivities 
in studies using higher frequency transducers, these studies varied 
in other ways, which may have confounded the results. 
Exciting advances continue to be made in developing less 
expensive, more portable, and more rugged ultrasound units with 
power options including battery and solar power(52-55). Although 
many of these systems have been developed for non-breast 
applications, continued advances in breast imaging applications, 
including higher frequency transducer development, will support 
expansion of breast ultrasound into more remote areas.  
This review revealed several limitations in the available data 
that constrain our ability to assess the performance of ultrasound 
in LMICs. The small number of studies from LMICs, and the 
variations in study populations and methods for determination 
of final outcome (biopsy type, with or without follow-up), are 
particular challenges. For example, in the two studies that 
included only patients with solid lumps, one might have expected 
a lower level of ultrasound performance, since researchers agree 
that ultrasound is good at distinguishing solid from cystic lesions 
but less effective at differentiating benign from malignant solid 
lesions (56); however, that was true in only one study. Another 
inconsistency was whether the number of cases reported included 
the number of lesions or number of patients. Few of the studies in 
lower-income settings had at least two-year follow-up of negative 
cases, so we should be cautious in interpreting negative predictive 
values. 
Despite the shortage of advanced technologies for breast cancer 
screening, diagnosis, and treatment in many LMICs, more can and 
must be done with existing resources to improve access to services. 
Addressing the burden of breast cancer requires educating women 
and their healthcare providers so they can recognize and act on 
symptoms of breast cancer, such as palpable lumps or focal pain 
(9). Providers must be able to refer women with suspicious findings 
on CBE and ultrasound to appropriate pathology services (FNA or 
CNB) to confirm diagnoses. Additional research is also needed to 
determine the feasibility of and strategies for bringing treatment 
interventions such as surgery, hormone receptor testing, and 
chemotherapy within reach of women confirmed to have cancer. It 
is early and appropriate treatment, and not simply early detection 
and diagnosis, that save lives. 
 
Conclusion
Overall, despite considerable variability in study design and 
patient populations, results of reviewed studies in high-resource 
areas and a limited number of LMICs consistently show the value 
of breast ultrasound in evaluating women with a positive CBE. 
These findings, despite their limitations, are encouraging. Our 
search found only a handful of studies reporting performance in 
low-resource countries, and we encourage more studies to assess 
the accuracy of ultrasound in these settings and the feasibility of 
widespread implementation. ☐
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